Market-Cap $49 Million-- Cash $19 Million or untill end 2020 -- Shares Out 9.1 Million -- Potential FDA approval for their lead drug Anjeso (non-opioid pain reliever ) in Q1 2020 which has HUGE market potential .MASSIVE underpriced and undicovered low float stock with significant upside potential here ..My target is $20+ by end of next year .GL Baudax Bio (BXRX) Market Cap 49 M Cash $19 M Price $5.45 Shares Out 9.1 M New Presentation (december 2019) https://d1io3yog0oux5.cloudfront.ne...XRX+2019+Dec+Corporate+Overview+vFINAL(1).pdf Janney starts Baudax Bio at buy; fair value estimate $12 https://biotuesdays.com/2019/11/22/janney-starts-baudax-bio-at-buy-fair-value-estimate-12/ Baudax’s key product is Anjeso, a long-acting intravenous formulation of meloxicam, an established non-opioid pain reliever, available through an oral formulation. “We see a high probability of FDA approval in the first quarter of 2020, which would be a meaningful catalyst to drive the stock towards our fair value,” writes analyst Ester Hong. She estimates peak U.S. sales of $355-million for Anjeso but sees “upside from increased demand for a potent non-opioid that allows patients to recover and go home faster.”
GREAT buying opp ahead of the NDA resubmission likely to hit the wire next week ...Could minimum double before FDA decision which will ouccur 2 months after NDA resubmission around March or April
Baudax Bio Inc. (BXRX) PT Raised to $12 at Oppenheimer https://www.streetinsider.com/Analy...PT+Raised+to+$12+at+Oppenheimer/16351861.html
Great News out today ....FDA DECISION NEXT MONTH (FDA) has set a PDUFA goal date of February 20, 2020 https://finance.yahoo.com/news/baudax-bio-announces-pdufa-date-120010357.html
Any dip here is a great buying opp ahead of the FDA decision next month ,stock likely tohit $10 in the coming days .GL
FDA approval is very likely this time ,, Approval would make this undiscovered stock worth more than $50 per share https://ir.recropharma.com/press-re...eal-to-recro-pharma-for-iv-meloxicam-new-drug "The FDA’s letter states that the appeal was granted “specific to the request…that the NDA provides sufficient evidence of effectiveness and safety to support approval.” The letter also states that “before IV meloxicam can be approved and legally marketed, agreed-upon labeling (prescribing information) must be negotiated with the Division.”
Still a massive buying opportunity after FDA approval at current laughable valuation of only $87 million Baudax Bio's (BXRX) Non-opioid Pain Drug Makes It To The Finish Line ... https://www.rttnews.com/3071353/bau...ug-makes-it-to-the-finish-line.aspx?refresh=1 ANJESO that will be administered as a once-a-day intravenous (IV) bolus push is the only available 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) and offers once-daily dosing. Baudax expects ANJESO to be available in the U.S. in late April or early May 2020. Esther Hong, an analyst at Janney Montgomery, estimates peak sales of the drug in the U.S. to reach about $355 million.
